Prime Number Acquisition I Corp (PNAC) Peer Comparison
$4.26
$-3.77
(-46.95%)
As on 25-Aug-2023 16:00EDT
Market cap
$29 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
1.7
P/B Ratio
0
Div. Yield
0 %
Edit
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
29 | 5,305 | 3,348 | 778 | 451 |
Revenue ($ Mln) |
-- | 440 | 2,883 | -- | 330 |
Net Profit ($ Mln) |
0.46 | -1,435.01 | -118.30 | -134.20 | 100.20 |
Net Margin (%) |
47.78 | -325.91 | -4.10 | -- | 30.33 |
RoE (%) |
-- | -- | -- | -40.17 | 30.44 |
Price to Earnings |
1.73 | -- | -- | -- | 4.72 |
Price-To-Book |
-- | -- | 1.35 | -- | 1.32 |
Income Statement ($ Mln)
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 640.31 | 3,083.80 | 32.22 | 220.79 |
|
Cost of Revenue
|
-- | 631.91 | 2,207.90 | 0.30 | 177.11 |
|
Gross Profit
|
-- | 8.40 | 875.90 | 31.92 | 43.68 |
|
Operating Expenses
|
0.64 | 884.89 | 736.30 | 162.14 | 42.00 |
|
Operating Profit (EBIT)
|
-0.64 | -244.57 | 139.60 | -129.92 | 1.68 |
|
Other Income
|
0.93 | -- | 0.00 | 0.86 | -46.21 |
|
Profit before Tax
|
0.29 | -2,163.41 | 5.40 | -131.76 | 1.68 |
|
Provision for Tax
|
0.15 | 15.76 | 14.30 | -- | 26.23 |
|
Profit after Tax (Net Income)
|
0.14 | -2,146.32 | -0.30 | -131.76 | -469.86 |
|
Minority Interest
|
-- | -- | -- | -- | 19.55 |
|
Consolidated Profit
|
0.14 | 47.31 | -0.34 | -131.76 | -469.86 |
Liabilities ($ Mln)
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-2.14 | -409.35 | -780.40 | 286.12 | -180.18 |
|
Minority Interest
|
-- | -- | -- | -- | 19.55 |
|
Non-Current Liabilities
|
66.72 | 1,030.24 | 2,739.20 | 76.52 | 154.16 |
|
Current Liabilities
|
2.54 | 186.79 | 2,108.80 | 63.02 | 134.40 |
|
Total Liabilities
|
67.12 | 807.69 | 4,412.70 | 425.65 | 2,839.35 |
Assets ($ Mln)
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.00 | 722.58 | 3,260.70 | 156.48 | 507.32 |
|
Current Assets
|
67.12 | 85.10 | 1,152.00 | 269.18 | 2,324.69 |
|
Total Assets
|
67.12 | 807.69 | 4,412.70 | 425.65 | 2,839.35 |
|
Total Debt*
|
0.35 | 818.81 | 3,183.70 | 23.64 | 154.58 |
|
Net Current Assets
|
64.58 | -101.69 | -956.80 | 206.16 | -- |
Cashflow ($ Mln)
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.63 | 205.19 | 346.10 | -75.62 | -173.11 |
|
Cash Flow from Investing Activities
|
-65.79 | -423.84 | 31.30 | 92.22 | 236.84 |
|
Cash from Financing Activities
|
66.57 | 306.15 | -394.50 | 1.08 | -25.39 |
|
Net Cash Inflow / Outflow
|
0.15 | -- | 1.42 | 17.68 | 38.33 |
Ratios
Profitability Ratios
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-16.09 | -621.90 | -0.01 | -34.71 | -202.05 |
|
ROE (%)
|
-13.43 | 3,339.12 | 0.06 | -39.23 | -619.15 |
|
ROA (%)
|
0.42 | -371.96 | -0.01 | -27.90 | -16.97 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
15.29 | -335.20 | -0.01 | -398.26 | -269.13 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.18 | 0.14 | -0.50 | -0.03 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-- | -4,636.52 | -102.70 | -138.01 | -711.23 |
|
EPS Growth (%)
|
-- | -31.35 | -1.00 | -1.24 | -7.09 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -0.21 | -5,142.26 | -19.34 | -0.10 |
|
Price / Book Value
|
-- | -1.12 | -1.98 | 8.91 | -0.25 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
78.55 | 70.38 | 2.46 | -17.58 | -11.78 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
14.80 | 2.92 | -4.08 | 0.08 | -0.86 |
|
Short term debt to equity ratio
|
14.80 | 0.37 | -1.24 | 0.07 | -0.01 |
|
Current Ratio
|
26.42 | 0.46 | 0.55 | 4.27 | 17.30 |
|
Quick Ratio
|
-- | -- | 0.53 | 4.26 | 20.23 |
|
Interest Coverage
|
-0.69 | -2.53 | 1.03 | -49.89 | 1.18 |
Operating Efficiency Ratios
| Prime Number Acquisition I Corp (PNAC) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 0.04 | 28.46 | 1.28 | 778.28 |
|
Asset Turnover
|
0.00 | 1.11 | 0.71 | 0.07 | 0.08 |
|
Receivable days
|
-- | 0.55 | 93.08 | 3.29 | 2,311.60 |
|
Inventory Days
|
-- | -- | 2.27 | 1,029.23 | -782.19 |
|
Payable days
|
-- | 15.58 | 37.06 | 11,865.18 | 473.60 |
|
Cash Conversion Cycle
|
-- | -- | 58.29 | -10,832.66 | 1,055.81 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
